Uncategorized Archives - Page 34 of 134

WednesdayOct 05, 2022 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering,…

TuesdayOct 04, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002 This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported The company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the drug was safe and well tolerated. Results from this study were well received by the SRC, who also expressed their optimism for Odyssey’s completion of the MAD portion of its Phase I trial…

MondayOct 03, 2022 10:45 am

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmia HeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhere BEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States (https://ibn.fm/FN4BR), and recent reports suggest that COVID-19 may cause heart problems (https://ibn.fm/7QAky) and that the incidence of heart…

WednesdaySep 28, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needs Its brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatments The company is also developing medical devices such as the intranasal drug delivery device, CardioMap, and Save-A-Life Scientists and specialists describe concussion, which is also referred to as mild traumatic brain injury (“mTBI”), as a spectrum. On the one hand, some concussed patients fully recover and do not require medical intervention or attention; on the other,…

TuesdaySep 27, 2022 10:30 am

NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%

A lot of football players often suffer concussions because their sports usually involve contact. Concussions are brain injuries caused by a blow to an individual’s head, which may or may not result in the loss of consciousness. These injuries sometimes cause temporary cognitive symptoms and have no specific cure. Concussion symptoms include confusion, headaches, loss of memory, lack of coordination, nausea and vomiting, ringing in the ears, dizziness, excessive fatigue and sleepiness. Data from a 2017 study found that 99% of tested NFL players, 91% of college football players and 88% of CFL players suffered from various stages of chronic…

MondaySep 26, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Medical product developer Odyssey Health Inc. is dedicated to creating solutions for a variety of life-quality situations, such as early detection of heart disease, saving choking victims and treating nervous system ailments Odyssey Health’s primary focus has been advancing its combined device and drug solution for brain concussion injuries through the clinical test process to commercial fulfillment The therapeutic solution, currently known as PRV-002, is designed to deliver a synthetic neurosteroid to injured brain tissue, where it can reduce swelling and sustain needed blood flow The company’s human testing has demonstrated safety with “no serious adverse events,” and Odyssey is…

FridaySep 23, 2022 10:30 am

Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs

Endometriosis is a disorder that causes the tissue that lines the inside of the uterus to grow outside the reproductive organ. It is associated with menstrual irregularities and pain and is estimated to affect around 10% of American women of reproductive age. The condition develops into endometrial cancer when the endometrial cells grow out of control, leading to the development of a tumor. Unfortunately, there is no cure for endometriosis, and current treatments can only do so much to ease the condition’s symptoms so they don’t interfere with an individual’s day-to-day activities. Prior studies have found that patients with endometrial…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric…

TuesdaySep 20, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere In September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch products In August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI platform technology used to detect and diagnose heart attacks On November 15, 2021, HeartBeam had its IPO on the Nasdaq under ticker symbol ‘BEAT’ The company’s management team has significant experience in software…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Study Finds That Endometriosis Prognosis Worsens as CNS Metastasis Occurs

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search